Roivant Sciences Ltd. (NASDAQ:ROIV) Receives Average Recommendation of "Moderate Buy" from Analysts

Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the nine brokerages that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $17.69.

ROIV has been the topic of several research reports. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Roivant Sciences in a research report on Thursday, September 19th. Bank of America raised their target price on Roivant Sciences from $12.00 to $12.50 and gave the stock a "neutral" rating in a research note on Wednesday, September 11th. Finally, HC Wainwright reiterated a "buy" rating and set a $18.00 price objective on shares of Roivant Sciences in a report on Wednesday.

Insider Buying and Selling at Roivant Sciences

In other news, CEO Matthew Gline sold 1,983,257 shares of the firm's stock in a transaction that occurred on Monday, September 23rd. The stock was sold at an average price of $11.79, for a total value of $23,382,600.03. Following the completion of the sale, the chief executive officer now directly owns 17,870,543 shares of the company's stock, valued at $210,693,701.97. This trade represents a 9.99 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CAO Rakhi Kumar sold 250,000 shares of the company's stock in a transaction that occurred on Monday, September 23rd. The shares were sold at an average price of $11.89, for a total value of $2,972,500.00. Following the transaction, the chief accounting officer now directly owns 209,322 shares in the company, valued at approximately $2,488,838.58. This represents a 54.43 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 3,577,309 shares of company stock valued at $42,151,184. Insiders own 7.90% of the company's stock.

Institutional Trading of Roivant Sciences

A number of hedge funds have recently bought and sold shares of the stock. Mutual of America Capital Management LLC raised its stake in shares of Roivant Sciences by 0.4% in the second quarter. Mutual of America Capital Management LLC now owns 327,079 shares of the company's stock worth $3,457,000 after purchasing an additional 1,142 shares during the last quarter. Acadian Asset Management LLC increased its holdings in Roivant Sciences by 23.2% in the 2nd quarter. Acadian Asset Management LLC now owns 8,510 shares of the company's stock worth $89,000 after acquiring an additional 1,603 shares in the last quarter. Covestor Ltd raised its position in shares of Roivant Sciences by 9.1% during the 3rd quarter. Covestor Ltd now owns 19,190 shares of the company's stock worth $222,000 after purchasing an additional 1,605 shares during the last quarter. US Bancorp DE boosted its holdings in Roivant Sciences by 146.5% in the 3rd quarter. US Bancorp DE now owns 3,278 shares of the company's stock worth $38,000 after buying an additional 1,948 shares during the last quarter. Finally, Gladius Capital Management LP purchased a new stake in Roivant Sciences during the 3rd quarter worth approximately $35,000. Hedge funds and other institutional investors own 64.76% of the company's stock.

Roivant Sciences Stock Down 2.6 %

NASDAQ ROIV traded down $0.31 during trading hours on Thursday, reaching $11.64. 5,428,498 shares of the company's stock were exchanged, compared to its average volume of 5,840,885. The company has a market capitalization of $8.61 billion, a price-to-earnings ratio of 2.07 and a beta of 1.24. The company has a debt-to-equity ratio of 0.05, a quick ratio of 27.91 and a current ratio of 27.91. Roivant Sciences has a one year low of $8.56 and a one year high of $13.06. The company's 50-day moving average is $11.78 and its two-hundred day moving average is $11.31.

Roivant Sciences (NASDAQ:ROIV - Get Free Report) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.37) earnings per share for the quarter, missing analysts' consensus estimates of ($0.27) by ($0.10). Roivant Sciences had a net margin of 3,827.42% and a negative return on equity of 14.65%. The company had revenue of $4.48 million during the quarter, compared to the consensus estimate of $34.57 million. On average, analysts forecast that Roivant Sciences will post -1.14 EPS for the current fiscal year.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.